Leonard Frank X's Form 4 filing
NovoCure Ltd (NVCR) · filed Mar 7, 2023
- Accession no.
- 0001562180-23-002581
- Filed
- Mar 7, 2023
- Trade date
- Mar 3-7, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market sales total $1.03M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leonard Frank XCIK 0001822879 | Officer (President, CNS Cancers US) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2023 | Ordinary Shares | SSaleDisposed | −4,403 | $76.16 | −$335,332.48 | 63,490 | Direct | |
| Mar 3, 2023 | Ordinary Shares | SSaleDisposed | −888 | $76.16 | −$67,630.08 | 62,602 | Direct | |
| Mar 7, 2023 | Ordinary Shares | SSaleDisposed | −6,003 | $75.00F2 | −$450,225 | 56,599 | Direct | |
| Mar 7, 2023 | Ordinary Shares | SSaleDisposed | −2,315 | $75.59F3 | −$174,990.85 | 54,284 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 6,003 shares in multiple trades at prices ranging from $74.33 to $75.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 2,315 shares in multiple trades at prices ranging from $75.33 to $75.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.